Skip to main content
. 2011 Jun 9;82(3):273–287. doi: 10.1159/000327719

Fig. 6.

Fig. 6

Effects of imatinib and nilotinib treatments on the expression of pSmad2, pSmad3 and Smad7. Compared with the bleomycin treatment group, the expression of pSmad2 and pSmad3 was significantly lower in the nilotinib treatment group on days 14 and 21. The expression of Smad7 was significantly higher in the nilotinib treatment group on day 21. Data are representative of 3 separate experiments. Abbreviations are as in figures 1 and 5. * p < 0.05 for BLM vs. BLM + I or for BLM vs. BLM + N; ** p < 0.01 for BLM vs. BLM + I or for BLM vs. BLM + N.